Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma

  • STATUS
    Recruiting
  • End date
    May 8, 2024
  • participants needed
    153
  • sponsor
    Gilead Sciences
Updated on 19 January 2022
platelet count
filgrastim
granulocyte colony stimulating factor
measurable disease
bone marrow procedure
dexamethasone
lenalidomide
colony stimulating factor
neutrophil count
bortezomib
refractory multiple myeloma

Summary

The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies and to determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab + daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib + dexamethasone.

The primary objective of this study for the Dose Expansion Cohorts is to evaluate the efficacy of magrolimab in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma as determined by objective response rate (ORR).

Details
Condition Multiple Myeloma
Treatment Pomalidomide, Dexamethasone, Bortezomib, Daratumumab, Magrolimab
Clinical Study IdentifierNCT04892446
SponsorGilead Sciences
Last Modified on19 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

All Individuals
Individual has been previously diagnosed with MM based on the IMWG 2016 criteria and currently requires treatment
Individuals must have measurable disease as defined by 1 or more of the following
Serum monoclonal protein (M-protein) ≥ 0.5 grams per deciliter (g/dL) (greater than or equal to [≥] 5 grams per liter [g/L])
Urine M-protein ≥ 200 mg/24 hours (h)
Serum free light chain (SFLC) assay: involved SFLC level ≥ 10 mg/dL (100 mg/L) with abnormal SFLC ratio
Individuals must have received at least 3 previous lines of therapy for MM including
Individual has provided informed consent
an IMiD such as lenalidomide and a PI such as bortezomib
Individual is willing and able to comply with clinic visits and procedure outlined in the study protocol
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Life expectancy ≥ 3 months
Absolute neutrophil count (ANC) ≥ 1000 cells/dL (1.0 x 10^9/L); granulocyte colony-stimulating factor (G-CSF) is not permitted within 1 week of screening to meet eligibility criteria
Platelet count ≥ 75,000 cells/dL (75 x 10^9/L); platelet transfusion is not permitted within 1 week of screening to meet eligibility criteria
Hemoglobin ≥ 9.0 g/dL; no more than 4 units of packed Red blood cells (RBCs) are allowed in the 30 days prior to screening
Adequate liver function as demonstrated by the following
For Individuals with prior cardiac history such as ischemic heart disease, left ventricular ejection fraction ≤ 45%, symptomatic congestive heart failure, New York Heart Association (NYHA) Class III or IV heart failure, or other conditions that may be sensitive to demand ischemia, the hemoglobin must be ≥ 9.5 g/dL prior to initial dose of study treatment. Transfusions are allowed to meet hemoglobin eligibility criterion
Aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) ≤ 3.0 x ULN
Total bilirubin ≤ 1.5 x ULN (or ≤ 3.0 x ULN and primarily unconjugated if individual has a documented history of Gilbert's syndrome or genetic equivalent)
Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin
time ≤ 1.2; Individuals receiving anticoagulation treatment may be allowed to
Pretreatment blood cross-match completed
participate if INR is within the therapeutic range prior to alternate
assignment
Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception
Individuals must be willing to consent to mandatory pretreatment and on-treatment bone marrow biopsies (trephines)
Individuals must have adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min calculated by the Cockcroft-Gault formula or measured by 24 hours urine collection
Magrolimab in Combination with Daratumumab: In addition to fulfilling the inclusion criteria for all individuals, individuals who are assigned to receive magrolimab in combination with daratumumab should fulfill the following
Corrected serum calcium ≤ 2.9 millimoles per liter (mmol/L) (11.5 mg/dL); measures to reduce calcium to acceptable levels, such as a short course of steroids, bisphosphonates, hydration, or calcitonin are acceptable
Individuals must have CD38-positive myeloma and have not had prior anti-CD38 antibody therapy for at least 6 months prior to enrollment
No prior history of discontinuation of daratumumab due to toxicity
Prior treatment with pomalidomide is allowed if the Individual achieved at least a PR to the most recent pomalidomide therapy and will have had at least a 6-month treatment-free interval from the last dose of pomalidomide until first study treatment
No prior history of discontinuation of pomalidomide due to toxicity
No contraindication to dexamethasone
Magrolimab in Combination with Pomalidomide and Dexamethasone: In addition to
fulfilling the inclusion criteria for all Individuals, Individuals who are
following
assigned to receive magrolimab in combination with pomalidomide and
Prior treatment with a PI, including bortezomib, is allowed if the Individual achieved at least a PR to the most recent prior PI therapy, and will have had at least a 6-month PI treatment-free interval from the last dose until first study treatment
dexamethasone should fulfill the following
No prior history of discontinuation of bortezomib due to toxicity
No contraindication to dexamethasone
Magrolimab in Combination with Bortezomib and Dexamethasone: In addition to fulfilling
the inclusion criteria for all individuals, individuals who are assigned to
receive magrolimab in combination with bortezomib and dexamethasone should
fulfill the

Exclusion Criteria

Individuals with known amyloidosis including myeloma complicated by amyloidosis
Multiple myeloma of immunoglobulin M subtype
Individuals with Waldenstrom's macroglobulinemia
Individuals with myelodysplastic syndrome (MDS)
Individuals with solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia
Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS) syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes)
Glucocorticoid therapy (prednisone > 40 mg/day or equivalent) within 14 days prior to enrollment; corticosteroid therapy for hypercalcemia is allowed
Chemotherapy with approved or investigational anticancer therapeutics within 28 days prior to enrollment
Focal radiation therapy within 7 days prior to enrollment; radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment (ie, prior radiation must have been to less than 30% of the bone marrow)
Immunotherapy within 28 days prior to enrollment
Major surgery (excluding procedures to stabilize the vertebrae) within 28 days prior to enrollment
Positive serum pregnancy test
Breastfeeding female
Plasma cell leukemia (defined as either 20% of peripheral blood white blood cell (WBC) count comprised of plasma/CD138-positive cells) or circulating plasma cells ≥ 2 x 10^9/L
Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient
Current participation in another interventional clinical trial
Autologous stem cell transplant < 100 days prior to enrollment
Considered eligible to receive autologous or allogeneic stem cell transplant (SCT) at the time of enrollment
Allogeneic SCT for the treatment of MM within 6 months of enrollment or active graft-versus-host disease requiring immunosuppression
Significant neuropathy (Grade 3 to 4, or Grade 2 with pain) within 14 days prior to enrollment
Known inherited or acquired bleeding disorders
Known cirrhosis
Clinical suspicion or documentation of central nervous system (CNS) disease
Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, congestive heart failure, or New York Heart Association (NYHA) Class III or IV heart failure
Prior treatment with CD47 or signal regulatory protein alpha (SIRPα)-targeting agents
Acute active infection requiring systemic antibiotics, antiviral (except antiviral therapy directed against reactivation) or antifungal agents within 14 days prior to enrollment
Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which patients are not on active anticancer therapies and have had no evidence of active malignancy for at least 1 year. Other exceptions may be considered with sponsor approval. Previous hormonal therapy with luteinizing hormone-releasing hormone agonists for prostate cancer and treatment with bisphosphonates and receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors are not criteria for exclusion
Known active or chronic hepatitis B or C infection or human immunodeficiency virus (HIV) infection in medical history
Active hepatitis B virus (HBV) and/or active hepatitis C virus (HCV), and/or HIV infection following testing at screening
Individuals who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease
Individuals who test positive for HCV antibody. Patients who test positive for HCV antibody will require HCV ribonucleic acid (RNA) by quantitative PCR for confirmation of active disease
Individuals who test positive for HIV
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note